IDH1 and central nervous system cancer: In 38 patients with glioma, mutations in IDH1/2 (n = 4, 10.5%), TERT promoter (n = 15, 39.5%), 1p/19q codeletion (n = 1, 2.6%), and H3-3A (n = 1, 2.6%) were detected.